In the foreseeable future, findings from ongoing clinical trials with ralmitaront and ulotaront will be fundamental to elucidate the therapeutic utility of TAAR1 agonists, which hold great promise as a new drug class for the treatment of schizophrenia. The gene discussed is TAAR1; the disease is schizophrenia.